ImmunityBio (IBRX) Shareholder Alert: Lead Plaintiff Deadline for Class Action Lawsuit

Investors who hold shares of ImmunityBio, Inc. (NASDAQ: IBRX) and have suffered substantial losses are urged to take immediate note of a fast-approaching legal deadline. ClaimsFiler, a trusted securities litigation alert platform, has issued a formal reminder for eligible shareholders to act before the lead plaintiff cutoff in the pending class action lawsuit against the clinical-stage biotech company.

This alert applies specifically to investors who have realized losses exceeding $100,000 on their IBRX holdings. Missing the deadline could limit your ability to seek recovery for investment losses tied to alleged securities law violations.

What Is the ImmunityBio (IBRX) Class Action Lawsuit?

The class action lawsuit against ImmunityBio, Inc. alleges violations of federal securities laws, including potential misleading statements or material omissions made by the company to investors. These alleged actions purportedly caused artificial inflation of IBRX stock prices, leading to significant losses when the true information came to light.

While specific details of the allegations are outlined in court filings, affected investors do not need to follow every legal development to preserve their right to recovery. Eligible shareholders can join the class action without taking on upfront legal costs, as most securities litigation firms work on a contingency fee basis.

Who Qualifies to Participate in the IBRX Class Action?

Not all IBRX investors are eligible to join the class action. You must meet the following criteria:

• Purchased or acquired ImmunityBio (IBRX) securities during the class period defined in the lawsuit filing
• Incurred total realized losses exceeding $100,000 on your IBRX holdings
• Wish to either serve as lead plaintiff or participate in the class-wide recovery

Note that you do not need to have held your IBRX shares continuously through the present date to qualify. Investors who sold their positions at a loss during the class period are still eligible.

Critical Date: Lead Plaintiff Deadline

The lead plaintiff is the investor (or group of investors) who represents the entire class in the lawsuit, and the deadline to apply for this role is fast approaching. To be considered for lead plaintiff status, eligible investors must file a motion with the presiding court by the cutoff date.

Even if you do not wish to serve as lead plaintiff, you can still participate in any eventual settlement or judgment recovery. However, registering your claim early ensures you receive all case updates and do not miss additional deadlines.

Steps for Affected IBRX Investors to Take Now

If you meet the eligibility criteria, follow these steps immediately to protect your rights:

1. Gather all transaction records for your IBRX purchases and sales, including dates, share counts, and total losses.
2. Visit ClaimsFiler.com to access free case details, eligibility checks, and required filing forms.
3. Consult with a qualified securities litigation attorney to review your specific situation and options.
4. Submit all required documentation before the lead plaintiff deadline to preserve your claim.

About ClaimsFiler

ClaimsFiler is a free alert service designed to help retail and institutional investors stay informed about pending securities class action lawsuits. The platform provides no-cost case evaluations, filing assistance, and regular updates on case progress for eligible investors.

Investors can sign up for free alerts on IBRX and other securities litigation at ClaimsFiler.com, with no obligation to file a claim.

Why Timely Action Matters

Securities class action lawsuits often take 12–36 months to resolve, but missing the lead plaintiff deadline can forfeit your right to shape the direction of the case. Even if you plan to join the class later, registering early ensures you do not miss critical notices or settlement distribution deadlines.

With losses exceeding $100,000, affected IBRX investors have significant potential recovery at stake. Taking 10 minutes to review your eligibility could make a major difference in your ability to recoup losses.

Final Reminder

Eligible ImmunityBio (IBRX) shareholders should not delay. The lead plaintiff deadline is non-negotiable, and courts rarely grant extensions. Visit ClaimsFiler.com today to confirm your eligibility and start the filing process.

For additional questions, contact ClaimsFiler’s support team directly through their website. Stay informed, protect your investments, and exercise your rights as a shareholder.